Linda Vahdat, M.D.
Linda Vahdat, MD MBA is a Professor of Medicine and Director of the Breast Cancer Research Program at Weill Cornell Medical College, leading research teams within the Division of Medical Oncology and the Meyer Cancer Center. She has been Cornell faculty since July 2002 and for 3. 5 years until Jan 2015 also was Chief of the Solid Tumor Service. She is a breast cancer expert with a focused clinical and research interest in high-risk adjuvant and metastatic breast cancer.
She has strong expertise in drug development, having had a crucial role in the last two chemotherapy drugs approved for metastatic breast cancer (ixabepilone, FDA-approved in 2007 and eribulin, FDA-approved in 2010) and with leadership roles in many other recent approved drugs and ones that are poised to be approved . She is involved in the initiation, conceptual design and conduct of pre-clinical and Phase 1,2 and 3 clinical trials.
Dr. Vahdat is board certified in Medical Oncology. Since completing her MBA at Sloan School of Management at MIT, she has shifted her focus to bring innovative and disruptive drugs and technology to market utilizing her newly expanded skill set. She has had and continues to have leadership positions in a number of professional societies including the American Society of Clinical Oncology (ASCO). Dr. Vahdat has published over 100 articles in peer-reviewed journals and several textbook chapters including one on targeted therapy for breast cancer. Her research interests include breast cancer, metastasis biology, new drugs, and new technology.